Analysis of the Pathological Mechanism and Clinical Efficacy of UVB Phototherapy for Psoriasis and Chronic Eczema
1. Fundamental Mechanism of UVB Phototherapy
Medium-wave ultraviolet (UVB) radiation, with a wavelength range of 280–320 nm, penetrates the skin's surface to reach the dermis, exerting multiple therapeutic effects on inflammatory skin diseases like psoriasis and chronic eczema. Its core pathological mechanisms include:
Inhibition of Keratinocyte Hyperproliferation: UVB interferes with cellular DNA synthesis, slowing down the abnormal proliferation of epidermal cells. This directly reduces the thickness and extent of psoriatic plaques.
Immunomodulatory Effects: UVB radiation suppresses the activity of local T-lymphocytes and reduces the release of pro-inflammatory cytokines (such as TNF-α and IL-8), thereby alleviating skin inflammation.
Promotion of Skin Barrier Repair: In chronic eczema, UVB can reduce inflammatory infiltration in the dermis, improve the function of the skin barrier, and relieve symptoms like itching and dryness.
2. Study Design and Methodology
This study enrolled 300 patients with psoriasis or chronic eczema, randomly divided into two groups:
Experimental Group (n=150): Received UVB phototherapy three times per week for a total of 6 weeks.
Control Group (n=150): Received conventional drug therapy, primarily topical corticosteroids and anti-inflammatory medications.
Disease severity was assessed before and after treatment using the Psoriasis Area and Severity Index (PASI) for psoriasis and the Eczema Area and Severity Index (EASI) for eczema. The Dermatology Life Quality Index (DLQI) was used to evaluate quality of life.
3. Analysis of Treatment Efficacy
3.1 Significant Improvement in Disease Severity
PASI Scores:
Experimental Group: Decreased from 18.5 to 8.2.
Control Group: Decreased from 18.7 to 15.4.
The improvement in the experimental group was significantly greater (P<0.001).
EASI Scores:
Experimental Group: Decreased from 20.0 to 9.1.
Control Group: Decreased from 19.8 to 17.3.
The experimental group again showed superior improvement (P<0.001).
The results indicate that UVB phototherapy is significantly more effective than conventional drug therapy in controlling lesion area and severity.
3.2 Marked Enhancement in Quality of Life
DLQI Scores:
The experimental group's score improved from 15 to 5.
The control group's score improved from 15 to 10.
The improvement in the experimental group was significantly greater (P<0.001).
This demonstrates that UVB treatment not only alleviates clinical symptoms but also significantly enhances patients' daily functioning and psychological well-being.
4. Safety Assessment
The incidence of adverse reactions (such as mild to moderate skin erythema and dryness) showed no significant difference between the two groups (Experimental: 20.00%, Control: 18.00%, P=0.143). All recorded adverse events were manageable and did not lead to treatment discontinuation or serious health issues.
Conclusion: UVB phototherapy demonstrates a favorable safety and tolerability profile alongside its high efficacy.
5. Discussion and Future Perspectives
UVB phototherapy directly intervenes in the pathogenesis of psoriasis and eczema through its anti-proliferative, immunomodulatory, and anti-inflammatory effects. Its significant efficacy and controllable side effects make it suitable for long-term management.
Future development directions include:
Personalized Treatment: Tailoring UVB dosage and frequency based on individual skin type and disease severity.
Combination Therapy: Integrating UVB with pharmacological treatments and lifestyle interventions to form comprehensive treatment regimens.
Summary
UVB phototherapy is an effective, safe, and pathologically well-founded treatment modality. It significantly improves clinical symptoms and quality of life for patients with psoriasis and chronic eczema, supporting its widespread application in clinical practice.
Tel/Whatsapp:+8619972563753
Email:bwzm12@benweilighting.com
Skype:bwzm32
Web:https://www.benweilight.com/
